Prostate Cancer NEWS You Can Use

Us TOO news e-messages

Us TOO Prostate Cancer NEWS You Can Use

Astellas and Medivation Receive Priority Review from FDA for XTANDI® (Enzalutamide) Capsules In Chemotherapy-Naive Advanced Prostate Cancer

TOKYO and SAN FRANCISCO, May 6, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) and Medivation Inc. (NASDAQ: MDVN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) to extend the indication for XTANDI® (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer ...

Teva and OncoGenex Announce Top-Line Survival Results of Phase III SYNERGY Trial Evaluating Custirsen in Combination with First-line Docetaxel and...

Teva and OncoGenex Announce Top-Line Survival Results of Phase III SYNERGY Trial Evaluating Custirsen in Combination with First-line Docetaxel and Prednisone for Metastatic Castrate-Resistant Prostate Cancer By a News Reporter-Staff News Editor at Cancer Weekly -- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced results from the Phase ...

Genomic Health Announces Presentation of Multiple Oncotype DX® Studies in Breast, Prostate, Colon and Renal Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting

REDWOOD CITY, Calif., May 5, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX® in breast, colon, prostate and renal cancer will be presented at the American Society of Clinical Oncology® (ASCO®) Annual Meeting, taking place May 30 - June 3, 2014 at McCormick Place in Chicago. New data, including two oral presentations, ...

Nymox Reports New Prostate Cancer Clinical Trial Results

Nymox Pharmaceutical Corporation (Nasdaq: NYMX) announced today new positive outcome results from the Company's ongoing prospective trial of NX-1207 for the treatment of low grade localized prostate cancer. These are the first clinical patient treatment outcome results for this trial. A controlled comparison was conducted of patients who required and received radiation and surgery treatments ...

IsoRay's Cancer Fighting Cesium-131 Isotope in Published Report Shows Significant Results in Early Clinical Interstitial Implants for Gynecologic Malignancies

IsoRayInc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the publication of the first major peer reviewed study showing improved results usingIsoRay'sCesium-131 seeds in the treatment of gynecologic cancer.IsoRayCEO Dwight Babcock commented, "We are very excited to have our Cesium-131 isotope seeds ...

Prostate Cancer: Watch and Wait or Ignore and Wait?

By a News Reporter-Staff News Editor at Cancer Weekly -- A long-term European study highlighted key patient compliance issues in the prostate cancer active surveillance strategy. In lieu of proactive prostate cancer treatments such as robotic prostate surgery, hormone therapy, or radiation, some men choose to postpone treatment and monitor the progression of their disease. Researchers found ...

BPH Patients Are Not Safe Taking Testosterone, While Dr. Allen's Device Terminates Prostate Enlargement and Increases Energy Naturally, States Fine Treatment

London, GB (PRWEB) May 03, 2014 Fine Treatment recommends that a man with benign prostatic hyperplasia (BPH) should use Dr. Allen's Device in the first place, as it diminishes the enlarged prostate size naturally relieving lower urinary tract symptoms and increasing male energy. At the same time, commonly used to boost a man's energy testosterone, according to the article in the WWL-News, it ...

Vitamin D: A Sunny Outlook for Prostate Cancer

NEW YORK, NY -- (Marketwired) -- 05/08/14 -- Vitamin D deficiency could be a predictor for aggressive prostate cancer, according to a study funded by The National Institutes of Health and the U.S. Department of Defense. In examining the prostate biopsy results of men with abnormal prostate-specific antigen (PSA) levels and/or digital rectal exams (DREs), researchers discovered that men with ...

New model can predict therapy outcomes in prostate cancer with bone metastasis

By a News Reporter-Staff News Editor at Cancer Weekly -- PHILADELPHIA - A new computational model that simulates bone metastasis of prostate cancer has the potential to rapidly assess experimental therapy outcomes and help develop personalized medicine for patients with this disease, according to data published in Cancer Research, a journal of the American Association for Cancer Research (see ...

Memorial Sloan-Kettering's Dr. Howard Scher Reaffirms Commitment to Lead Phase I Trials for AV Therapeutics' Prostate Cancer Drug

NEW YORK, May 7, 2014 (GLOBE NEWSWIRE) -- AV Therapeutics, Inc. ("AV Therapeutics" or the "Company") (OTCQB:AVTH), a developer of cancer therapeutics and vaccines, announced Howard Scher, MD, Chief, Genitourinary Oncology Service and D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center, reaffirmed his commitment to lead AV Therapeutics' Phase I clinical trial ...

Prostate Cancer Foundation Receives over $8.4M Movember Donation

SANTA MONICA, Calif.--(BUSINESS WIRE)-- The Prostate Cancer Foundation (PCF) has received over $8.4 million from its partner Movember, the global men’s health charity that gets men to grow and women to support the moustache for the month of November, raising vital funds and awareness for men’s health. PCF will allocate the over $8.4 million to find better treatments and ultimately a cure, by ...

New Addition to the Prostate Cancer Roundtable Policy Agenda Addresses Quality-of-Life Endpoints

WASHINGTON, Dec. 18, 2013 /PRNewswire/ -- The Prostate Cancer Roundtable has updated its shared national policy agenda for 2014 to include a new policy priority, based on the idea that Phase III clinical trials of new drugs and other forms of treatment that are being tested for their ability to extend overall or progression-free survival should, at the same time, be evaluated for their impact ...

Astellas and Medivation Submit Supplemental New Drug Application for XTANDI (Enzalutamide) for Chemotherapy-Naive Advanced Prostate Cancer

TOKYO, JAPAN and SAN FRANCISCO, CA -- (Marketwired) -- 03/18/14 -- Astellas Pharma Inc. (TSE: 4503) and Medivation Inc. (NASDAQ: MDVN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of XTANDI® (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) ...

MRI-Guided Prostate Biopsy Improves Accuracy and Patient Comfort

NEW YORK, NY -- (Marketwired) -- 04/07/14 -- During trial, a new MRI-guided prostate biopsy yielded more targeted prostate tissue retrieval and improved diagnosis accuracy. The combined multiparametric magnetic resonance imaging (mpMRI) and magnetic resonance (MR) guided biopsy (MRGB) techniques reduced the incidence of low-risk prostate cancer diagnosis and improved overall detection of ...

Six months hormone therapy in addition to radiotherapy improves prostate cancer survival

The findings, which will be presented at the 33rd conference of the European Society for Radiotherapy and Oncology (ESTRO33) in Vienna today (Monday), are expected to change clinical practice. Professor Michel Bolla, a professor of radiation oncology at Grenoble University Hospital (Grenoble, France), will tell the conference: "Although we need longer follow-up to assess the impact on these ...

Surgery may be best for young men with prostate cancer

Younger men who have been diagnosed with prostate cancer may do well to consider surgery over so-called ”watchful waiting,“ a new study shows. The new research, published in the New England Journal of Medicine, is unlikely to end the long-running debate in the medical community over if and when surgery to remove the prostate is needed - particularly since the men in the study were diagnosed ...

Younger men with prostate cancer did well after surgery

Prostate cancer surgery improved survival among men diagnosed at a younger age or with intermediate-risk disease, U.S. and Swedish researchers say. Study co-author Jennifer Rider of the Harvard School of Public Health and assistant professor of medicine at Brigham and Women's Hospital, and colleagues at the Uppsala University Hospital in Sweden used data from the Scandinavian Prostate Cancer ...

New test detects prostate cancer recurrence with much more accuracy

Washington, Apr 6 (ANI): Researchers in Canada have developed a new genetic "signature" to identify prostate cancer patients who are at high risk of their cancer recurring after surgery or radiotherapy. Professor Robert Bristow said that although surgery and precision radiotherapy are the mainstays of treatment for cancer that is confined to the prostate, the cancer will return in between ...

Medication does not help prevent ED following radiation therapy for prostate cancer

By a News Reporter-Staff News Editor at Cancer Weekly -- Among men undergoing radiation therapy for prostate cancer, daily use of the erectile dysfunction drug tadalafil, compared with placebo, did not prevent loss of erectile function, according to a study in the April 2 issue of JAMA. Erectile dysfunction (ED) is a common condition resulting from many causes, including prostate cancer ...

Radium-223 dichloride in prostate cancer: Major added benefit for certain patients

By a News Reporter-Staff News Editor at Clinical Trials Week -- Radium-223 dichloride (radium-223 for short, trade name: Xofigo) has been approved since November 2013 for men with advanced prostate cancer, in whom hormone blockade is no longer effective, and symptomatic bone metastases, but without visceral metastases. In an early benefit assessment pursuant to the Act on the Reform of the ...

Data on Clinical Trials and Studies Reported by Researchers at Cancer Research Institute

By a News Reporter-Staff News Editor at Clinical Trials Week -- Data detailed on Clinical Research have been presented. According to news reporting originating from Nashville, Tennessee, by NewsRx correspondents, research stated, "The androgen receptor pathway remains active in men with prostate cancer whose disease has progressed following surgical or medical castration. Orteronel (TAK-700) ...

U.S. Trial for Prostate Cancer Treatment via Ultrasound Ablation

NEW YORK, NY -- (Marketwired) -- 04/08/14 -- Though not yet available in the U.S., ultrasound ablation is part of the prostate cancer treatment spectrum in other countries. MRI-guided treatment is currently in clinical trials in the U.S. for low-risk prostate cancer, though it is yet to be approved by the Federal Drug Administration (FDA). Based on preliminary results, researchers believe the ...

Patent Application Titled "Anti-Alpha-V Integrin Antibody for the Treatment of Prostate Cancer" Published Online

By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application by the inventors Hoffmann, Axel (Wehrheim, DE); Lannert, Heinrich (Schwetzingen, DE); Brischwein, Klaus (Muenchen, DE); Pipp, Frederic Christian (Gruendau, DE); Reindl, Juergen (Rossdorf, DE); Groll, Karib (Muehltal, DE); Zuehlsdorf, ...

Findings from Department of Radiation Oncology Yields New Data on Prostate Cancer

By a News Reporter-Staff News Editor at Cancer Weekly -- A new study on Oncology is now available. According to news reporting originating in Athens, Greece, by NewsRx journalists, research stated, "The purpose of this study was to compare the planning approaches used in two treatment planning systems (TPS) provided by Elekta for VMAT treatments. Ten prostate patients were studied ...

Findings on Clinical Trials and Studies Discussed by Investigators at University of Gothenburg

By a News Reporter-Staff News Editor at Clinical Trials Week -- Fresh data on Clinical Research are presented in a new report. According to news reporting from Gothenburg, Sweden, by NewsRx journalists, research stated, "To compare the survival outcomes of patients treated with surgery or radiotherapy for prostate cancer. Observational study. Sweden, 1996-2010. Participants 34 515 men ...

New Prostate Cancer Study Findings Have Been Reported by Investigators at Royal Adelaide Hospital

By a News Reporter-Staff News Editor at Cancer Weekly -- A new study on Oncology is now available. According to news reporting from Adelaide, Australia, by NewsRx journalists, research stated, "Pelvic radiotherapy may lead to changes of anorectal function resulting in incontinence-related complaints. The aim of this study was to systematically review objective findings of late anorectal ...

Reports from National Pingtung University of Science and Technology Advance Knowledge in Prostate Cancer

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology. According to news reporting originating from Pingtung, Taiwan, by NewsRx correspondents, research stated, "Neuroendocrine (NE) differentiation has been attributed to the progression of castration-resistant prostate cancer (CRPC). Growth factor pathways including the epidermal growth factor ...

Studies from Istanbul Kultur University Add New Findings in the Area of Prostate Cancer

By a News Reporter-Staff News Editor at Cancer Weekly -- Research findings on Oncology are discussed in a new report. According to news originating from Istanbul, Turkey, by NewsRx correspondents, research stated, "Androgen signaling is critical in prostate cancer development and progression. The co-existence of hormone responsive and irresponsive cells due to functional androgen receptor (AR) ...

Today: Patients, Caregivers and Healthcare Providers from Across NY Travel to Albany to Urge Senate to Pass Comprehensive Medical Marijuana...

Today: Patients, Caregivers and Healthcare Providers from Across NY Travel to Albany to Urge Senate to Pass Comprehensive Medical Marijuana Legislation ALBANY, N.Y., Feb. 26 -- The Drug Policy Alliance issued the following news release: Today, over a dozen patients, families, caregivers and healthcare providers will gather in Albany to press the State Senate to pass the Compassionate Care Act ...

Republican Support for Comprehensive Medical Marijuana Bill Continues to Grow

NEW YORK, Feb. 24 -- The Drug Policy Alliance issued the following news release: Today, in meeting with the Breast Cancer Coalition of Rochester, Senator Joseph Robach (R, C, IP - Rochester) stated his support for the Compassionate Care Act, a bill that would allow New Yorkers with serious and debilitating conditions to access to medical marijuana (http://www.drugpolicy.org/medical-marijuana) ...

CLICK HERE and opt-in to receive free educational emails from Us TOO.